Consequently, an in-depth investigation of the intrinsic mechanisms of osimertinib resistance is essential for developing new targeted agents to overcome resistance and improve the prognosis of patients with NSCLC carrying EGFR-activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.